What is Zimmer Biomet?

What is Zimmer Biomet?

Zimmer Biomet is a public orthopedic medical devices company headquartered in Warsaw, IN. Zimmer Biomet reported full-year 2025 net sales of $8.232 billion, up 7.2% as reported and 3.9% organic constant currency.

Zimmer Biomet operates in orthopedic medical devices with a portfolio that includes Knee implants, Hip implants, ROSA Robotics, Sports medicine. Zimmer Biomet reported full-year 2025 net sales of $8.232 billion, up 7.2% as reported and 3.9% organic constant currency. The company employs about 20,000+ and trades as NYSE: ZBH, so its buying motion looks like a regulated enterprise account rather than a startup account.

Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Zimmer Biomet through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.

For sellers, Zimmer Biomet is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.

Sources:Zimmer Biomet 2025 resultsZimmer Biomet annual reports

What does Zimmer Biomet offer?

Zimmer Biomet offers products and services across Knee implants, Hip implants, ROSA Robotics, Sports medicine and related healthcare workflows.

Sources:Zimmer Biomet websiteZimmer Biomet annual reports

How does Zimmer Biomet make money?

Zimmer Biomet earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.

Zimmer Biomet earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $8.232B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.

Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.

Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Zimmer Biomet improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.

Sources:Zimmer Biomet 2025 resultsZimmer Biomet annual reports

Who leads Zimmer Biomet?

Zimmer Biomet is led by Ivan Tornos, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.

Sources:Zimmer Biomet leadershipZimmer Biomet annual reports

How do you contact Zimmer Biomet's leadership?

Zimmer Biomet publishes official Zimmer Biomet investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.

• Ivan TornosPresident and Chief Executive Officerofficial Zimmer Biomet investor-relations contact route
• Suketu UpadhyayExecutive Vice President and Chief Financial Officerofficial Zimmer Biomet investor-relations contact route
• Sang YiGroup President, Asia Pacificofficial Zimmer Biomet investor-relations contact route

Sources:Zimmer Biomet contactZimmer Biomet leadership

How much funding has Zimmer Biomet raised?

Zimmer Biomet is a mature public company, not a venture-backed startup. It trades as NYSE: ZBH and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.

Zimmer Biomet's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.

As of June 2026, the current capital lens is NYSE: ZBH, $8.232B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.

Seller signal: Zimmer Biomet has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.

Sources:Zimmer Biomet 2025 resultsNYSE: ZBH market data

How did Zimmer Biomet get here?

Zimmer Biomet grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.

Sources:Zimmer Biomet annual reportsZimmer Biomet 2025 results

Who are Zimmer Biomet's competitors?

Zimmer Biomet competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.

Sources:Zimmer Biomet annual reportsZimmer Biomet website